Cardiovascular disease (CVD) affects men and women differently with women having a lower incidence and later onset of disease. Research has recently refocused interest on the cardiovascular role of androgens. The purpose of this review is to summarize the evidence available on the association between testosterone and cardiovascular health in postmenopausal women. Published studies relating testosterone and sex hormone-binding globulin (SHBG) to CVD and its risk factors were reviewed. Studies included in this review suggest that increased androgenicity, characterized by high testosterone and low SHBG levels, is associated with an adverse CVD risk factor profile in postmenopausal women. However, evidence for an association with cardiovascular events is lacking and it is uncertain whether the observed associations with endogenous testosterone have clinical implications regarding the use of postmenopausal testosterone therapy. Large-scale, longitudinal studies relating testosterone and SHBG levels to cardiovascular risk factors and endpoints are needed to determine the temporal relationship between androgenicity and cardiovascular risk and to ascertain the long-term efficacy and safety of testosterone therapy in postmenopausal women.
Introduction
Cardiovascular disease (CVD) is the leading cause of death among women worldwide. Although the incidence of CVD is much lower in premenopausal women compared with men of similar age, the CVD rate in women rises steadily after the age of 50 years. 1, 2 Initially, this increase in CVD incidence later in life was ascribed to the menopausal decline of estrogen levels. 3 However, throughout the years, several observations have brought this theory into question. Studies examining associations between endogenous estrogen levels and CVD risk factors have yielded conflicting results [4] [5] [6] and available data on CVD events indicate a lack of association. 7, 8 Furthermore, in contrast to other estrogen related diseases, the CVD rate does not show a sharp rise at time of menopause. 1, 2, 9 In addition, several trials have failed to show a beneficial effect of estrogen replacement therapy in postmenopausal women, [10] [11] [12] further weakening the estrogen protection hypothesis.
Owing to the controversial role of estrogens in women's cardiovascular health, recent research has gradually turned more focus to the potential effects of androgens. Indirect evidence for a role of androgens comes from findings of clinical studies showing an unfavorable cardiovascular risk profile in hyperandrogenic conditions such as hirsutism 13 and the polycystic ovary syndrome.
14 Several studies in postmenopausal women have also shown a positive correlation between testosterone and various CVD risk factors. 5, [15] [16] [17] These findings have raised questions regarding the safety of testosterone administration to postmenopausal women. 18 However, reverse associations between testosterone and markers of atherosclerosis have been reported as well. 19, 20 This review aims to summarize the current evidence on the role of endogenous testosterone in cardiovascular health in postmenopausal women and to highlight potential adverse effects of testosterone therapy.
Search strategy and selection criteria
For this review we searched for English language articles in PubMed and EMBASE using the key words 'androgens', 'sex hormones', 'sex steroids', 'testosterone' and 'sex hormone-binding globulin' in combination with 'cardiovascular' and 'women'. In addition, we checked reference lists of retrieved articles. To exclude confounding by postmenopausal hormone therapy, we excluded observational studies that included postmenopausal women on hormone therapy. For reviewing the association between hormones and cardiovascular risk factors, we further focused on studies that excluded subjects with prevalent metabolic and cardiovascular conditions (for example, diabetes, heart disease and stroke) or studies that adjusted for these conditions in their analyses.
Testosterone production and action
In women, testosterone circulates in levels that are about 5% of those observed in men. There are three main sources of testosterone production in women: (1) the ovary, (2) the adrenal cortex and (3) peripheral conversion of androgen precursor hormones (androstenedione, dehydroepiandrosterone (DHEA), dehydroepiandrosterone sulfate (DHEA-S)). The secretion of testosterone from the ovary is stimulated by luteinizing hormone, with estradiol exerting negative feedback. In the adrenal cortex, the secretion of testosterone is stimulated by adrenocorticotropic hormone with negative feedback by cortisol. In premenopausal women, 25% of testosterone is derived from ovaries, 25% from adrenals and 50% is produced by peripheral conversion. These three sources of circulating testosterone are slightly redistributed in postmenopausal women, because of the menopause and age-related atrophy of the adrenal cortex. 21 With the follicular depletion during menopause, estradiol production decreases rapidly, leading to a loss of negative feedback at the pituitary. The resulting increase in luteinizing hormone levels drives the ovarian production of testosterone. 22, 23 Although the ovaries remain active in naturally postmenopausal women, the adrenocortical secretion of testosterone and androgen precursor hormones decreases gradually because of the agerelated atrophy of the adrenal cortex. This explains the lower proportion of testosterone that is derived from the adrenal cortex (10%) and peripheral conversion (40%) in postmenopausal women ( Figure 1 ).
In men, circulating testosterone levels decline with aging. 24 Whether a similar age-related trend occurs in women remains controversial. Crosssectional studies have reported an age-related decrease in testosterone levels starting from the early reproductive years to the age of 65 years, followed by a small increase in late years. 25, 26 However, recent insights from a longitudinal study suggest that circulating testosterone levels increase rather than decrease in women aged 38-50 years. 27 Testosterone exerts its biologic effects directly or through its metabolites (dihydrotestosterone (DHT) and estradiol). In local tissues, a small fraction of testosterone is metabolized by the enzyme Figure 1 Testosterone production in postmenopausal women. Abbreviations: ACTH, adrenocorticotropic hormone; DHT; dihydrotestosterone; LH, luteinizing hormone; DHEA, dehydroepiandrosterone; DHEA-S, dehydroepiandrosterone sulfate. þ , stimulatory; À, inhibitory.
Testosterone and SHBG in female vascular health JS Brand and YT van der Schouw 5a-reductase to DHT, which has a higher molar potency because of its higher affinity for the androgen receptor. The androgenic action is diversified by the aromatase (CYP19) mediated conversion of testosterone to estradiol.
Measuring testosterone levels
In the circulation, testosterone is specifically bound to sex hormone-binding globulin (SHBG) (B66%) and non-specifically to albumin (B33%), leaving only a small fraction unbound or free (B1-2%). Historically, free testosterone (FT) and bioavailable testosterone (BT), which includes both free and albumin-bound testosterone, have been considered to be the bioactive fractions able to diffuse across cellular membranes. However, increasing evidence suggests that even SHBG-bound testosterone mediates the cellular uptake and biological actions of testosterone. 28, 29 As SHBG is present in such a large excess in postmenopausal women, FT and BT levels are primarily driven by SHBG. The hepatic production of SHBG is regulated positively by estradiol and negatively by testosterone. Therefore, increased testosterone levels in hyperandrogenic conditions not only raise FT levels directly, but also indirectly by lowering SHBG levels.
Given the low circulating levels of testosterone, highly sensitive and accurate assays are required to obtain reliable results in women. Mass spectrometry is the gold standard for the measurement of total testosterone (TT). However, most laboratories use direct immunoassays, as they are more rapid and less time consuming. FT and BT levels can be measured directly or calculated by algorithms (for example, Sodergard 30 and Vermeulen 31 ). The limitations in measuring testosterone have been well reviewed recently. 32 To obtain more reliable TT measurements in female samples and to ensure accurate estimation of FT and BT levels, extraction and chromatography before the testosterone assay have been recommended.
Cardiovascular risk factors and disease
Over the past years, several observational studies have examined the relationship between endogenous testosterone and CVD and its risk factors. Tables 1-5 summarize the reported associations of TT, SHBG, BT and FT with various indicators of CVD risk. It is important to emphasize the limitations of the observational studies being summarized here. Study populations were heterogeneous and selection criteria diverse. For example, the type of menopause (surgical, natural or mixed) varied between study populations. Furthermore, adjustment for potential confounding factors was not always adequate. The majority of studies did not adjust for estradiol (E2), which could be a potential confounder because postmenopausal estradiol is mainly derived from peripheral aromatization of testosterone. Another limitation is that most studies used direct immunoassays (without extraction), which are suboptimal for the measurement of TT levels in postmenopausal women. Furthermore, the selection of poorly matched controls may have introduced bias in case-control studies because CVD patients are more likely to be on medication and to have modified their lifestyle. Finally, atherogenic changes may cause a decline in serum testosterone levels in patients with CVD, increasing the likelihood of spurious associations in casecontrol studies.
Body composition and blood pressure Obesity and hypertension are important predictors of cardiovascular morbidity and mortality in postmenopausal women. 76, 77 Cross-sectional findings on the relationship between TT and markers of obesity are somewhat conflicting with either an increase Abbreviations: BMI, body mass index; BT, bioavailable testosterone; DBP, diastolic blood pressure; FT, free testosterone; SBP, systolic blood pressure; TT, total testosterone; SHBG, sex hormone-binding globulin; WHR, waist-to-hip ratio; m, positive association; k, negative association; ¼ , no significant association.
Testosterone and SHBG in female vascular health JS Brand and YT van der Schouw or no change in body mass index (BMI), waist circumference and waist-to-hip ratio (WHR) with increasing TT levels ( Table 1) . None of the studies, however, suggested that high TT levels were associated with decreased obesity. Associations with SHBG, BT and FT seem to be more consistent: increased BMI, waist circumference and WHR are related to an increase in BT and FT levels, and a decrease in SHBG levels. It has been suggested that testosterone and SHBG are more strongly related to abdominal obesity than general obesity. 33, 44 In the study of Kaye et al., 44 the association between SHBG and WHR remained significant after adjusting for BMI. Few studies have examined the relationship with measures of body fat distribution. Phillips et al. 39 reported a positive correlation between FT and visceral fat mass in healthy postmenopausal women. Two studies reported an inverse association between SHBG and visceral fat tissue. 41, 47 In another study, including pre-, peri-and postmenopausal women, high BT and low SHBG levels were also found to be associated with an increase in visceral fat, independently of age, insulin resistance and estradiol. 78 As all studies used a cross-sectional design, the causal direction of the reported associations cannot be ascertained. The reversal direction, for instance, is supported by studies showing a decrease in testosterone levels after weight and body fat loss in overweight women. 79, 80 Furthermore, adipose tissue, with its 17b-hydroxysteroid dehydrogenase activity, has been suggested to be an important site of peripheral testosterone production. 81, 82 On the other hand, testosterone treatment has been associated with changes in body composition, including a redistribution of fat depots. In female-to-male (FM) Abbreviations: BT, bioavailable testosterone; FT, free testosterone; HDL-C, high-density lipoprotein-cholesterol; LDL-C, low-density lipoprotein-cholesterol; SHBG, sex hormone-binding globulin; TT, total testosterone; m, positive association; k, negative association; ¼ , no significant association. Abbreviations: BT, bioavailable testosterone; FT, free testosterone; SHBG, sex hormone-binding globulin; TT, total testosterone; m, positive association; k, negative association; ¼ , no significant association.
Testosterone and SHBG in female vascular health JS Brand and YT van der Schouw transsexuals, testosterone administration (250 mg intramuscular testosterone ester injections every 2-3 weeks) causes a decrease in subcutaneous fat, while increasing BMI and visceral fat mass. [83] [84] [85] In obese postmenopausal women, a similar increase in visceral fat and decrease in subcutaneous fat have been reported after administration of a weak androgen (nandrolone decanoate). 86 Similarly, high doses of exogenous testosterone increase BMI and visceral fat mass in female cynomolgus monkeys. 87 A role of testosterone in the development of visceral adiposity is further supported by observational data. In healthy middle-aged women, baseline BT and change in BT levels predicted the accumulation of visceral fat 5 years later, independently of estradiol and weight changes. 88 Recent findings from Zang et al. 89 also support an impact of testosterone on fat metabolism. In subcutaneous fat tissue from postmenopausal women, a decrease in hormone sensitive lipase expression was observed after oral administration with testosterone undecanoate. This may explain the shift of fat accumulation towards the visceral abdominal area. In this study, testosterone undecanoate also increased the expression of phosphodiesterase-3B, an enzyme involved in the anti-lipolytic action of insulin in adipocytes.
The relationship between androgenicity and blood pressure has been studied less frequently and with less consistent results ( Table 1) . Two studies 5, 43 failed to show an association between testosterone and blood pressure. In contrast, Haffner et al. 17 found a positive association of TT with systolic and diastolic blood pressure. Furthermore, high FT and low SHBG levels have been reported in postmenopausal women with hypertension. 54, 58 Testosterone may influence blood pressure through the induction of obesity. However, several studies 17, 58 have showed that the association between testosterone and blood pressure is independent of BMI, suggesting a direct effect on the reninangiotensin-aldosterone system (RAAS). Experimental data also support a direct effect of testosterone. In female rats, testosterone treatment increases renin activity and angiotensinogen expression. 90, 91 Moreover, high testosterone levels have been associated with increased vasoconstriction in sucrose-fed female rats 92 and increased levels of endothelin, a potent vasoconstrictor, in postmenopausal women. 15 Glucose and insulin metabolism Table 2 summarizes the cross-sectional and longitudinal studies that examined the association between testosterone, SHBG and markers of glucose and insulin metabolism. In most studies no significant association with TT was found. Some of these studies, however, may have been limited by a small sample size and lack of control for confounders. Lambrinoudaki et al. 5 observed an independent association between TT and insulin resistance in a large study of 598 postmenopausal women. Similarly, another study including a large number of incident diabetes cases showed a significant association between TT and type 2 diabetes after multivariable adjustment. 38 Unlike TT, SHBG and bioactive fractions of testosterone show stronger associations with markers of glucose and insulin metabolism. BT, FT and SHBG have repeatedly been associated with type 2 diabetes, although one study failed to show an association with SHBG. 40 This study may have been underpowered (n ¼ 49) to detect an association.
The underlying nature of the observed associations seems to be complex. The associations may in part be mediated by obesity. Although the associations of SHBG with insulin sensitivity and type 2 diabetes seem to be independent, 16 
The temporal nature of the associations is also not completely resolved. Longitudinal studies support a causal role for testosterone and SHBG in glucose and insulin metabolism. Androgen administration reduces insulin sensitivity in young, regularly menstruating women 93 and peripheral glucose uptake in FM transsexuals. 94 Similarly, antiandrogen therapy partially improves insulin sensitivity in hyperandrogenic women. 95, 96 In addition, rat experimental data show that testosterone impairs insulinmediated glucose uptake at the skeletal muscle by reducing the expression of glycogen synthase. 97, 98 There is, however, also some evidence that hyperinsulinemia could give rise to increased androgen levels. Insulin inhibits hepatic SHBG production in vitro. 99 Simultaneously, insulin stimulates ovarian testosterone production 100 and luteinizing hormone release from pituitary cells. 101 Furthermore, suppression of insulin levels by metformin therapy reduces androgen levels in polycystic ovary syndrome women. 102 These observations suggest that the association of androgenicity with insulin resistance and type 2 diabetes may be an epiphenomenon, with insulin determining circulating levels of SHBG and testosterone. Remarkably, none of the studies relating testosterone or SHBG to type 2 diabetes adjusted for this potential confounding effect of insulin. However, in middle-aged women lower SHBG levels have been associated with type 2 diabetes risk independent of fasting insulin levels. 103 Recent findings from a Mendelian randomization study show an association between SHBG polymorphisms and type 2 diabetes, further supporting a causal role of SHBG in glucose and insulin metabolism. 54 
Lipid profile
Results from observational studies do not support a major role for testosterone in lipid metabolism. A few studies reported an inverse association of TT with high-density lipoprotein cholesterol (HDL-C) and a positive association with total cholesterol, low-density lipoprotein cholesterol (LDL-C) and triglycerides, but in most studies no significant correlation between TT and lipid parameters was found (Table 3) . Available data regarding the associations of BT and FT with lipid parameters are also inconsistent (Table 3 ). In contrast, low levels of SHBG have consistently been associated with a pro-atherogenic lipid profile, namely increased triglyceride and decreased HDL-C levels. Nevertheless, clinical observations suggest a role for testosterone in dyslipidemia. Women with polycystic ovary syndrome have an abnormal lipid profile, characterized by elevated triglyceride and reduced HDL-C levels. 104, 105 In FM transsexuals, testosterone administration has been associated with a reduction in HDL-C and an increase of triglyceride levels. 83 In obese, postmenopausal women administration of nandrolone decanoate 86 causes a decrease in HDL-C and an increase in LDL-C levels. These clinical and experimental data suggest that greater androgenicity is required to induce an atherogenic lipid profile. The mechanisms through which testosterone and SHBG affect lipid metabolism are not completely understood, although direct regulatory effects on hepatic lipase (HL) and lipoprotein lipases (LPLs) have been reported. HL and LPL are key enzymes involved in the regulation of triglyceride and HDL-C levels. LPL activity causes a decrease in triglyceride and an increase in HDL-C levels, whereas HL activity is associated with a decrease in HDL-C. In FM transsexuals, testosterone therapy has been reported to increase HL activity. 83 The sensitivity of lipolytic enzymes for androgens is further supported by findings from the HERITAGE study showing a strong inverse association between SHBG and HL activity and a positive association between SHBG and LPL activity. 106 Apart from direct regulatory effects, testosterone and SHBG may also influence lipid metabolism indirectly through their associations with obesity. Yasui et al. 60 found that associations of SHBG with HDL-C and triglycerides were no longer significant after controlling for BMI. In another study, a similar lack of independence was observed for the association with HDL-C. 64 Conversely, in several studies associations between SHBG and triglycerides 5, 6, 55, 64 and HDL-C 5,17 persisted after adjustment for BMI or WHR. In the study of Lambrinoudaki et al., 5 associations of TT and FT with triglycerides and HDL-C were not explained by BMI. However, it should be noted that this study did not investigate the impact of body fat, which could be a stronger confounder in this relationship. Phillips et al. 39 found that after controlling for visceral fat mass, the positive association between FT and triglyceride levels remained significant, whereas the association between FT and HDL-C lost significance.
Another possible mediator is insulin. Insulin is known to exert a direct regulatory effect on HL and LPL. 107, 108 Interestingly, only a few studies 6, 52, 56 adjusted for the effect of insulin. Mudali et al. 6 showed that adjustments for insulin, BMI and other covariates did not significantly influence associations of SHBG with HDL-C and triglycerides. In contrast, Soler et al. 52 found that associations between SHBG and triglycerides were lost after controlling for WHR, insulin and estradiol. In the study of Haffner et al. 56 the association of SHBG with HDL-C was independent of fasting insulin levels, but the relationship with triglycerides lost significance after adjusting for insulin.
Other cardiovascular risk factors
Besides traditional risk factors, a growing number of studies have started to examine associations with other markers of cardiovascular risk such as Testosterone and SHBG in female vascular health JS Brand and YT van der Schouw C-reactive protein (CRP), fibrinogen and white blood cell count (Table 4) . CRP is an inflammatory marker and independent predictor of cardiovascular events in postmenopausal women. 109 In several studies, higher BT levels and lower SHBG levels 34, 54, 66, 69 have been associated with an increase in CRP levels. In addition, a positive association between TT and CRP has been reported in healthy postmenopausal women. 15, 34 Conversely, Joffe et al. 67 found an opposite association in women referred to coronary angiography, with low testosterone levels being associated with an increase in CRP levels. Interestingly, this inverse association with testosterone was not present in women who remained CVD-free. These findings suggest that the association between testosterone and CRP depends on CVD status, with a potential confounding effect of subclinical CVD. Early atherogenic changes may affect testosterone production by the ovaries and adrenals through restriction of the blood supply. This may explain the presence of the reverse association among women with subclinical CVD.
Data on the association between testosterone and the clotting factor fibrinogen are inconclusive. In two small studies, 15, 68 TT levels were not related to plasma fibrinogen levels. However, in a larger study including 317 postmenopausal women, 66 fibrinogen levels were approximately 10% higher in highest TT quartile compared with the lowest quartile, but no association between SHBG and fibrinogen was found. Interestingly, high TT levels in this study were also associated with an increase in white blood cell count, another promising marker for CVD.
Atherosclerosis
Studies investigating the relation between testosterone and atherosclerotic indices (carotid, aortic, coronary and peripheral atherosclerosis) have yielded contradictory results (Table 5) .
Phillips et al. 75 examined the correlation between testosterone and the degree of coronary atherosclerosis in a cross-sectional design among 60 patients with coronary artery disease. In this study, increasing FT levels were associated with coronary artery disease severity, independent of estradiol, BMI and other cardiovascular risk factors. In the WISE study 72 positive associations of TT and FT with coronary artery disease turned significant after adjustment for estradiol levels. Ouyang et al. 70 focused on a population of postmenopausal women without clinically evident CVD and found that high TT and BT levels and low SHBG were associated with subclinical carotid atherosclerosis. The associations with TT and BT were independent of age, BMI and cardiovascular risk factors, but the association with SHBG lost significance after adjustment for HDL and LDL cholesterol. In the Rotterdam Study, 71 higher levels of TT tended to be associated with aortic atherosclerosis in postmenopausal women, although this association was diluted after adjustments for cardiovascular risk factors. On the other hand, several studies have reported opposite results. Bernini et al. 19 showed an inverse association between FT and carotid intima-media thickness (cIMT) in 44 postmenopausal women. Similar findings were reported by Debing et al. 20 who found that cases with carotid atherosclerosis had lower levels of FT than atherosclerotic free controls. In another case-control study, 74 carotid atherosclerosis was also found to be more common in women in the lowest TT quartile than in the highest TT quartile. However, results from this latter study need to be interpreted with caution, as extreme outliers in hormone levels (which are likely to result from measurement errors) were not removed from analyses and may have caused spurious relations. Furthermore, it should be noted that reverse causality is a bigger issue in casecontrol studies. Atherosclerosis may affect testosterone production by impairing the blood flow to androgen-producing organs. This could partly explain the discrepancy in results. Alternatively, the contradictory findings may indicate the presence of a U-shaped relationship in which very low testosterone levels (below the physiological range) and high testosterone levels compromise arterial function. This theory is supported by studies showing impaired endothelial function in postmenopausal women with low testosterone levels 110 and increased carotid atherosclerosis and endothelial dysfunction in polycystic ovary syndrome women with supraphysiological testosterone levels. 111, 112 Results from experimental studies show a similar pattern. Bruck et al. 113 showed an increase in plaque size after testosterone treatment in female rabbits on an atherogenic diet. This increase was independent of changes in plasma lipids. Similarly, testosterone treatment doubled the extent of coronary atherosclerosis in female cynomolgus monkeys fed an atherogenic diet for 24 h. 87 Testosterone has also been reported to increase vasoconstriction and to decrease vasodilatation in sucrose fed female rats, suggesting an adverse effect of testosterone on endothelial function. 92 In vitro data further suggest that testosterone may increase monocyte adhesion to the vascular endothelium. 114 On the other hand, testosterone has been reported to induce relaxation in rabbit coronary artery and aorta rings. 115 In addition, administration of physiological testosterone levels to androgen-deficient female rats improves the vasodilatory reserve of the vascular endothelium. 116 
Cardiovascular events and mortality
Relatively few data are available on the relationship between endogenous testosterone and cardiovascular Testosterone and SHBG in female vascular health JS Brand and YT van der Schouw events and mortality in postmenopausal women, which may indicate publication bias. In the Rancho Bernardo Study, 8 TT and BT levels did not differ between cases with and without CVD at baseline and did not predict cardiovascular mortality over a 19-year follow-up. Although the number of cardiovascular deaths was relatively high in this study (n ¼ 176), stratification for estrogen replacement therapy may have reduced power to detect an association. Contrary to the data on CVD risk factors, Haffner et al. 117 found that diabetic women in the lowest TT quartile had an increased risk of ischemic heart disease mortality, although this association was no longer significant in multivariable adjusted analyses. As the authors pointed out, the lack of a positive association may result from a plateau effect in which variations in testosterone levels may not contribute to ischemic heart disease mortality in diabetic women who are already androgenized. In a large nested casecontrol study 7 higher BT levels were associated with an increased risk of cardiovascular events, although this association was not independent of BMI, hypertension and diabetes.
Data on the relationship between SHBG and CVD are also mixed. Haffner et al. 117 failed to show an association between SHBG and ischemic heart disease mortality in diabetic women. In the Gothenburg Study, 118 a U-shaped association between SHBG and myocardial infarction was found, with a high incidence of myocardial infarction in the lowest decile of SHBG. However, this study did not adjust for BMI. In the Rancho Bernardo study, 119 which adjusted for BMI, no significant association between SHBG and CVD mortality was found; however, women with higher SHBG levels had slightly lower CVD and ischemic heart disease mortality rates. Similarly, Rexrode et al. 7 found that low SHBG levels increased the risk of CVD events, although this relationship was not independent of BMI.
Postmenopausal testosterone therapy
There is increasing interest in the use of testosterone as part of postmenopausal hormone therapy. In several studies addition of testosterone to estrogen therapy has been reported to improve sexual function and well-being. 120, 121 In addition, beneficial effects on bone mineral density have been observed. 122 Despite the large number of studies investigating the effects of testosterone coadministration, there are limited long-term data regarding the cardiovascular safety of this combination therapy. Treatment duration ranges from 1 month to 2 years and no studies to date have investigated the effects on cardiovascular events (Table 6) . Two studies 139, 141 reported adverse effects on atherosclerotic indices in naturally postmenopausal women. Penotti et al. 139 showed that 8-month coadministration of high-dose testosterone undecanoate (40 mg per day) causes a small, but significant increase in the pulsatile index of the middle cerebral artery, but not in the internal carotid artery. In a retrospective study, Hak et al. 141 found an adverse effect of long-term, high-dose intramuscular estrogen-testosterone therapy on aortic atherosclerosis. In addition, an increase in fibrinogen levels has been reported with oral methyl testosterone therapy. 132 However, no significant changes in clotting factors have been found in surgically postmenopausal women treated with low-dose testosterone patches. [124] [125] [126] The effects of testosterone supplementation on lipids seem to depend on the route of administration (Table 6 ). Coadministration with oral methyltestosterone or testosterone undecanoate causes a decrease in HDL-cholesterol levels, whereas no significant change in lipid parameters is observed with testosterone patches or implants. Furthermore, oral preparations of methyltestosterone cause a favorable decrease in triglyceride levels, an effect which is not observed with transdermal testosterone. These differential effects are thought to be attributed to a first-pass liver effect, which is bypassed by implants and transdermal patches.
Available data on body composition suggest both beneficial and adverse effects. An increase in lean body mass and decrease in fat mass have been reported after coadministration of methyltestosterone 133 and testosterone implants. 122 In contrast, Leao et al. 136 described an increase in body weight and visceral fat mass after the addition of 1.25 mg methyltestosterone to transdermal estradiol therapy.
Regarding glucose metabolism, no adverse effects have been reported.
Altogether these findings indicate that short-term cardiovascular effects of testosterone coadministration depend on the dose and route of administration, with low-dose testosterone patches being the safest option. However, it is important to emphasize that co-treatment with estrogens may counteract potential adverse effects of testosterone. Therefore, safety data from testosterone coadministration studies cannot be used to draw firm conclusions about the cardiovascular effects of exogenous testosterone in postmenopausal women. Studies monitoring the effects of testosterone therapy only provide a better model for studying these effects. Only recently, the effect of testosterone only was investigated in a 52-week double-blind placebo-controlled trial 140 in which postmenopausal women received a patch delivering 150 or 300 mg of testosterone per day or placebo. In this study, circulating levels of TT, FT and BT showed a dose-related increase with testosterone treatment, but no difference in lipid profile and glucose metabolism was observed between women treated with testosterone compared with placebo. These findings do not correspond with the Testosterone and SHBG in female vascular health JS Brand and YT van der Schouw associations found in observational studies and the effects of exogenous testosterone reported in FM transsexuals and animal models. There are several explanations for these discrepant results. First of all, the dosages administered were lower than those used by FM transsexuals. Secondly, transdermal administration may exert different effects than the intramuscular injections administered to FM transsexuals and animal models. The duration of exposure may also not be sufficient to detect an effect. Finally, postmenopausal women in this study had symptoms of androgen deficiency and may therefore have a lower baseline CVD risk and be less susceptible to adverse effects of testosterone.
Conclusions
Studies reviewed in this article suggest that increased androgenicity (high endogenous testosterone and low SHBG levels) is associated with an adverse CVD risk factor profile in postmenopausal women. However, firm conclusions about the association between testosterone, SHBG and clinical CVD events cannot be drawn. Many studies were limited by a cross-sectional design and longitudinal data regarding the association with cardiovascular events were scarce and inconclusive. Existing data from testosterone supplementation studies further suggest that the use of low-dose transdermal testosterone is safe. However, studies examining potential adverse effects were often restricted by a short follow-up period. As testosterone replacement therapy is increasingly being used for the treatment of sexual dysfunction in postmenopausal women, its long-term effects on cardiovascular risk markers need to be studied more thoroughly. Although the effects of testosterone may be less detrimental than in FM transsexuals, because of the lower dosages being administered, the long-term safety of testosterone use needs to be assessed carefully as minor deleterious effects on CVD may outweigh the benefits of testosterone therapy.
There are several potential mechanisms linking increased androgenicity to an adverse CVD risk profile, including both direct and indirect effects. Experimental data suggest direct effects of testosterone on body composition, lipid levels and glucose metabolism. We postulate that increased androgenicity contributes to the accumulation of visceral fat and impairment of glucose metabolism, creating a vicious circle, whereby the increase in insulin and fat tissue in turn promote the production of Testosterone and SHBG in female vascular health JS Brand and YT van der Schouw testosterone. Apart from these direct effects, associations of androgen excess with glucose and lipid metabolism may be strengthened through the effects of testosterone on body composition. Associations between testosterone, SHBG and atherosclerotic indices seem to be mediated in part through their associations with CVD risk factors. Atherosclerosis in turn may lead to lower circulating testosterone levels by decreasing the blood supply to androgenproducing organs. Research into nontraditional CVD risk factors is growing and may identify alternative pathways through which androgens affect cardiovascular health.
Of particular interest is that SHBG is often more strongly related to the CVD risk profile than testosterone itself. As SHBG is correlated with testosterone, the independent contribution of SHBG to the CVD risk profile is unclear. The lack of strong associations with testosterone may also reflect the reliability of the testosterone assays currently being used. If SHBG does have an independent effect, its precise role requires further investigation. SHBG may influence CVD risk indirectly by modulating the biologic effects of testosterone or exert more direct effects through its own SHBG receptor.
There is need for more large-scale longitudinal studies examining the temporal relationship between endogenous testosterone and SHBG levels and cardiovascular risk and studies evaluating the long-term safety of testosterone replacement in postmenopausal women. In addition, Mendelian randomization studies may help to determine the likelihood of causality. Finally, more research is needed to elucidate the mechanisms through which testosterone and SHBG affect CVD risk and to indicate potential means of prevention and intervention.
